API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/03/27/2853117/0/en/Oncopeptides-and-Vector-Pharma-FZCO-Announce-Collaboration-to-Provide-Pepaxti-to-Patients-in-the-Middle-East-and-North-Africa.html
https://endpts.com/fda-formally-pulls-oncopeptides-cancer-drug-after-prolonged-back-and-forth/
https://endpts.com/cder-challenges-oncopeptides-appeal-over-pepaxto-withdrawal/
https://www.prnewswire.com/news-releases/oncopeptides-provides-update-on-pepaxto-us-marketing-authorization-301697069.html
https://www.prnewswire.com/news-releases/oncopeptides-pepaxti-has-been-granted-marketing-authorization-in-the-uk-301675786.html
https://www.fiercepharma.com/pharma/after-fda-defeat-oncopeptides-shows-results-small-study-shows-benefit-sidelined-pepaxto
https://www.pharmacompass.com/pdf/news/oncopeptidess-pepaxti-melphalan-flufenamide-receives-approval-in-europe-84795.pdf
https://www.prnewswire.com/news-releases/oncopeptides-phase-3-ocean-study-published-in-the-lancet-haematology-301460221.html
https://www.prnewswire.com/news-releases/oncopeptides-presents-new-melflufen-data-at-the-annual-american-society-of-hematology-meeting-ash-301442034.html
https://www.prnewswire.com/news-releases/oncopeptides-withdraws-pepaxto-in-us-scale-down-organization-and-focus-on-rd-301406644.html
https://www.fiercepharma.com/pharma/fda-warns-increased-death-risk-for-freshly-approved-myeloma-drug-threatening-potential
https://www.prnewswire.com/news-releases/oncopeptides-ab-phase-3-ocean-study-demonstrates-that-melflufen-is-at-least-as-efficacious-as-pomalidomide-the-most-used-medicine-in-relapsed-refractory-multiple-myeloma-301298329.html
https://www.prnewswire.com/news-releases/fda-approves-oncopeptides-pepaxto-melphalan-flufenamide-for-patients-with-triple-class-refractory-multiple-myeloma-301237310.html
https://www.prnewswire.com/news-releases/oncopeptides-submits-a-new-drug-application-to-the-fda-for-accelerated-approval-of-melflufen-in-triple-class-refractory-multiple-myeloma-patients-301085607.html
https://www.prnewswire.com/news-releases/oncopeptides-reinitiates-patient-enrollment-to-the-melflufen-clinical-program-following-a-temporary-pause-due-to-the-covid-19-pandemic-301066742.html